|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Plague | |||||
| 2 | More general conditions related to this trial | ||||
| Bacterial Infections | |||||
| Enterobacteriaceae Infections | |||||
| Gram-Negative Bacterial Infections | |||||
| Yersinia Infections | |||||
| 3 | Interventions listed in this trial | ||||
| gentamicin | |||||
| streptomycin | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Gentamicins | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Synthesis Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Centers for Disease Control and Prevention | |||||
| Food and Drug Administration (FDA) | |||||
| Ministry of Health, Madagascar | |||||
| Ministry of Health, Uganda | |||||